Navigation Links
Orqis(R) Medical Awarded 15th U.S. Patent
Date:4/23/2008

Intellectual Property Expands to 41 Patents in more than 20 Countries

LAKE FOREST, Calif., April 23 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to improve cardiac performance through Aortic Flow Therapy, announced today that the United States Patent and Trademark Office has issued U.S. Patent number 7,331,921 (the '921 patent) entitled "Implantable Heart Assist System and Method of Applying Same." The '921 patent which discloses and claims methods and apparatus for intravascular renal (kidney) perfusion is exclusively owned by Orqis and is the Company's 15th U.S. Patent.

Mr. Ken Charhut, President and CEO, Orqis Medical, stated, "This latest patent is the result of Orqis' aggressive intellectual property strategy to treat the cardio-renal syndrome and improve cardiac performance with less invasive treatment approaches." He continued, "Orqis is developing a large intellectual property footprint that addresses the treatment gap between medical management and more invasive procedures without ever touching the heart."

Orqis' patent portfolio now encompasses 15 U.S. Patents and 26 International Patents in over 20 countries.

About Heart Failure

Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over $33 billion in direct and indirect costs to the U.S. healthcare system each year.

About Orqis Medical Corporation

Orqis Medical Corporation is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System has secured the CE mark. The implantable Exeleras(R) System is in development.

For more information on Orqis Medical, please visit orqis.com

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.


'/>"/>
SOURCE Orqis Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Orqis(R) Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting
2. Best Practice Database Adds New Research on Effective Sales Force Incentives and Continuing Medical Education
3. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
4. Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University
5. Developing roadmaps for enhancing the professional culture of medical schools
6. UT Southwestern Medical Center receives grant from the Robert Wood Johnson Foundation
7. The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues
8. Changes to Family and Medical Leave Act Clarify Employer Responsibilities
9. Medical Breakthrough Reaches America
10. CRH Medical Corporation opens third Center in Chicago
11. Medicare to consider public opinion about medical maggots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
Breaking Medicine Technology: